Plasma exchange in the intensive care unit: a narrative review

Philippe R. Bauer1, Marlies Ostermann2, Lene Russell1, Chiara Robba4, Sascha David6, Bruno L. Ferreyro7, Joan Cid9, Pedro Castro4, Nicole P. Juffermans8, Luca Montini10, Tasneem Pirani13, Andry Vandeven12, Nathan Nielsen11, Julia Wendon18, Anne C. Brignier3, Miet Schetz16, Jan T. Kielstein9, Jeffrey L. Winters19, Elie Azoulay1 on behalf of the Nine-I Investigators

© 2022 Springer-Verlag GmbH Germany, part of Springer Nature

Abstract

In this narrative review, we discuss the relevant issues of therapeutic plasma exchange (TPE) in critically ill patients. For many conditions, the optimal indication, device type, frequency, duration, type of replacement fluid and criteria for stopping TPE are uncertain. TPE is a potentially lifesaving but also invasive procedure with risk of adverse events and complications and requires close monitoring by experienced teams. In the intensive care unit (ICU), the indications for TPE can be divided into (1) absolute, well-established, and evidence-based, for which TPE is recognized as first-line therapy, (2) relative, for which TPE is a recognized second-line treatment (alone or combined) and (3) rescue therapy, where TPE is used with a limited or theoretical evidence base. New indications are emerging and ongoing knowledge gaps, notably regarding the use of TPE during critical illness, support the establishment of a TPE registry dedicated to intensive care medicine.

Keywords: Plasma exchange, Plasmapheresis, Intensive care units, State-of-the-art review, Patient care team

Introduction

Therapeutic apheresis encompasses the removal of plasma (plasmapheresis) or blood cells (cytapheresis, i.e., erythrocytes, leukocytes, or platelets) from the patient's blood. If plasma is removed not for donation but for therapeutic purposes and is replaced by donor plasma, colloid, or crystalloids or a mixture thereof, it defines therapeutic plasma exchange (TPE) (Fig. 1). TPE serves to remove pathogenic substances (e.g., autoantibodies or toxic agents) and/or to administer deficient substances present in plasma of healthy donors (e.g., a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13, ADAMTS13) though other potential immunomodulatory effects may be involved [1]. The indications for TPE have been refined over time. Many patients who require TPE are critically ill needing admission to the intensive care unit (ICU). TPE is an invasive procedure with often emergent indications, demanding its execution as soon as possible. Thus, a rapid response by experienced staff, with specific equipment, close monitoring, and multidisciplinary management are essential.

The goal of this article is to present a narrative review of the main indications for TPE in critically ill patients, as well as their main characteristics. A multidisciplinary group of intensivists, immunologists, nephrologists, pathologists, and hematologists reviewed and summarized the evidence on the rationale and indications for...
TPE in the ICU, shared their experience, and identified relevant issues that need to be known by the intensivists, as well as knowledge gaps that need to be filled by future research.

**Indications for urgent TPE in critically ill patients**
The American Society for Apheresis (ASFA) updated its guidelines on therapeutic apheresis in 2019 [2], and the Japanese Society in 2021 [3]. They identified four categories of use: first-line therapy (Category I), second-line therapy (Category II), role not established (Category III), and ineffective or harmful (Category IV). In the ICU, the indications for TPE can be divided into (1) absolute, well-established, and evidence-based, for which TPE is recognized as first-line therapy, (2) relative, for which TPE is a recognized second-line treatment alone or combined with other interventions and (3) rescue therapy, where TPE is used with limited evidence of benefits but a plausible theoretical rationale (Table 1) [4–7].

**Mechanisms, kinetics, and goals of TPE**

**Mechanisms of TPE**
TPE has two mechanisms of action (Fig. 1):

1. Removal of a pathogenic substance from the plasma (e.g., IgG in myasthenia gravis, IgM in Waldenström macroglobulinemia, or IgG and IgM iso-agglutinins prior to ABO incompatible organ transplantation [8]). To be efficiently cleared by TPE, the substance should ideally be identified and assayed and have a high molecular weight, low distribution volume (chiefly in plasma), long half-life, and low turnover rate. Of note, the degree of substance removal does not necessarily correlate with the alleviation of the clinical symptoms like in myasthenia gravis [9].
2. Delivery of large amounts of deficient plasma components (e.g., ADAMTS13 in thrombotic thrombocytopenic purpura (TTP)). The fluid used for plasma

---

**Take-home message**
Therapeutic plasma exchange (TPE) procedures performed by trained personnel are a safe and effective therapeutic approach for patients suffering from diseases listed in the guidelines of the American Society for Apheresis.

The creation of a specific registry for TPE administered in the intensive care unit would allow for a robust database to assess efficacy and safety of TPE in critically ill patients.

1. Removal of a pathogenic substance from the plasma (e.g., IgG in myasthenia gravis, IgM in Waldenström macroglobulinemia, or IgG and IgM iso-agglutinins prior to ABO incompatible organ transplantation [8]). To be efficiently cleared by TPE, the substance should ideally be identified and assayed and have a high molecular weight, low distribution volume (chiefly in plasma), long half-life, and low turnover rate. Of note, the degree of substance removal does not necessarily correlate with the alleviation of the clinical symptoms like in myasthenia gravis [9].
2. Delivery of large amounts of deficient plasma components (e.g., ADAMTS13 in thrombotic thrombocytopenic purpura (TTP)). The fluid used for plasma
| Disease                                                                 | Rationale                                                                                           | Replacement fluid          | Adjunct therapeutic options | Strategy* and Endpoints                                                                 | Parameters to monitor                                                                 | Additional comments                                                                                                                                 |
|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------|------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barré syndrome) | Removal of antibodies                                                                             | Albumin or plasma           | MIG                          | 1–1.5 TPV, 5–6 sessions over 10–14 days until clinical improvement                      | Clinical response                                                                     | Consider TPE if failed to respond to IVIG and/or impending respiratory failure                                                                 |
| Anti-glomerular basement membrane disease (Goodpasture syndrome)       | Removal of pathogenic autoantibodies (including anti-GBM antibodies)                                | Albumin, plasma if bleeding  | Corticosteroids, cyclophosphamide, rituximab | 1–1.5 TPV daily or on alternate days over 10–20 days until disease control              | Renal function Clinical response                                                      | Anti-GBM antibodies may fall to undetectable levels within 2 weeks; TPE course should be ≥ 10–20 days and should continue until resolution of glomerular or pulmonary injury. The presence or absence of antibody should not guide decisions to initiate or end TPE. |
| Hyper-viscosity syndrome (in hyper-gammaglobulinemia, especially Waldenström macroglobulinemia) | Removal of paraproteins, thereby reducing the plasma viscosity                                       | Albumin or Albumin/saline   | Systemic chemotherapy or immunotherapy | 1–1.5 TPV daily until symptoms subside, most often 1–3 procedures                       | M component (mainly IgM levels)                                                       | Symptoms are more reliable than concrete values of viscosity or immunoglobulins to guide therapy                                               |
| Catastrophic antiphospholipid syndrome                                 | Removal of antibodies (including antiphospholipid antibodies, cytokines, and complement factors; administration of coagulation factors) | Plasma (± albumin)           | Anticoagulation, corticosteroids, MIG, rituximab or eculizumab | 1–1.5 TPV daily or alternate days; until clinical response                             | Clinical response                                                                     |                                                                                                                                                  |
| Myasthenia gravis                                                     | Removal of autoantibodies (including anticholinergic autoantibodies and immunomodulation)             | Albumin                     | Cholinesterase inhibitors, corticosteroids, immunosuppression, IVG, thymectomy, eculizumab | 1–1.5 TPV; 3–6 sessions over 10–14 days; until disease control                       | Clinical response                                                                     | More effective if initiated during myasthenic crisis, especially with bulbar or severe generalized response; more effective than IVIG in patients with MuSK-Ab |
| N-Methyl-D-aspartate receptor antibody encephalitis                    | Removal of antibodies (including anti-neuronal autoantibodies)                                       | Albumin                     | High dose corticosteroids, MIG, occasionally rituximab or cyclophosphamide Tumor resection (when tumor is present) | 1–1.5 TPV; 5–12 sessions over 1–3 weeks until clinical response                       | Clinical response                                                                     | Check for ovarian tumors and other tumors (germ cell tumors, carcinoma, teratoma, lymphoma)                                               |
| Disease | Rationale | Replacement fluid | Adjunct therapeutic options | Strategy* and Endpoints | Parameters to monitor | Additional comments |
|---------|-----------|-------------------|-----------------------------|-------------------------|----------------------|-------------------|
| Thrombotic thrombocytopenic purpura | Administration of ADAMTS13 protease and removal of anti-ADAMTS13 autoantibodies | Plasma | Corticosteroids, rituximab, Caplacizumab (recombinant ADAMTS13?) | Daily until platelet count > 150 x 10⁹/L, LDH approaching normal and resolution of non-fixed neurologic symptoms then Continue for 2 more sessions then stop | Platelet count, LDH, ADAMTS13 activity | Recovery of ADAMTS13 activity to >10% within 7 days is associated with clinical response |
| Acute liver failure | Removal of albumin-bound and water-soluble toxins Replacement of plasma proteins including clotting factors Immunomodulation Reduction of proinflammatory response | Plasma | Multiorgan support | High-volume TPE if possible (target 8–12 L); otherwise, 1–1.5 TPV daily until clinical improvement or transplantation | Clinical response | Supportive care as a bridge to liver transplantation |
| Acute disseminated encephalomyelitis | Removal of presumed pathogenic autoantibodies | Albumin | Corticosteroids, IVIG | 1–1.5 TPV every other day until disease control | Clinical response | Always consider TTP in the differential in specific scenarios (e.g., pregnancy and acute liver failure) Supportive care may improve nontransplant outcome Support care may stabilize while awaiting liver transplant |
| Thrombotic microangiopathy-complement-mediated (formerly known as atypical hemolytic syndrome (aHUS)) | Recommended while investigations for TTP and other forms of TMA are in progress or if eculizumab is not available | Plasma | Eculizumab | 1–1.5 TPV daily until TTP ruled out | Platelet count | |
| Autoimmune hemolytic anemia | Removal of pathogenic immune complexes, autoantibodies and complement components | Albumin | Corticosteroids, rituximab, IVIG, immunosuppression, monoclonal antibody therapy, splenectomy | TPV 1–1.5 daily until disease control | Clinical response | |

Relative indications: Disorders for which TPE is a recognized second-line treatment (alone or combined)

| Disease | Rationale | Replacement fluid | Adjunct therapeutic options | Strategy* and Endpoints | Parameters to monitor | Additional comments |
|---------|-----------|-------------------|-----------------------------|-------------------------|----------------------|-------------------|
| Thyroid storm (refractory) | Removal of autoantibodies, catecholamines, and cytokines | Plasma, albumin | Propylthiouracil, corticosteroids, ß-blockers, cholestyramine, organ support | Daily to every 3 days, until control of systemic response | Clinical response | Although a category II per 8th ASFA guidelines, TPE could be considered in refractory cases |
| ANCA-associated vasculitis with diffuse alveolar hemorrhage | Removal of autoantibodies and inflammatory mediators | Plasma | Corticosteroids, rituximab, cyclophosphamide | 1–1.5 TPV daily or every other day until disease control | Clinical response (resolution of pulmonary hemorrhage) | PEXMAS trial suggested no benefit on death or end stage kidney disease Now category II per recent ASFA update [73] |

| Disease | Rationale | Replacement fluid | Adjunct therapeutic options | Strategy* and Endpoints | Parameters to monitor | Additional comments |
|---------|-----------|-------------------|-----------------------------|-------------------------|----------------------|-------------------|
| Acute disseminated encephalomyelitis | Removal of presumed pathogenic autoantibodies | Albumin | Corticosteroids, IVIG | 1–1.5 TPV every other day until disease control | Clinical response | |
| Thrombotic microangiopathy-complement-mediated (formerly known as atypical hemolytic syndrome (aHUS)) | Recommended while investigations for TTP and other forms of TMA are in progress or if eculizumab is not available | Plasma | Eculizumab | 1–1.5 TPV daily until TTP ruled out | Platelet count | |
| Autoimmune hemolytic anemia | Removal of pathogenic immune complexes, autoantibodies and complement components | Albumin | Corticosteroids, rituximab, IVIG, immunosuppression, monoclonal antibody therapy, splenectomy | TPV 1–1.5 daily until disease control | Clinical response | |
| Disease                                                                 | Rationale                                                                 | Replacement fluid | Adjunct therapeutic options | Strategy<sup>a</sup> and Endpoints                                                                 | Parameters to monitor                                                                 | Additional comments                                                                 |
|-----------------------------------------------------------------------|---------------------------------------------------------------------------|-------------------|------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Chronic acquired demyelinating polyneuropathies (IgA- and IgG-associated polyneuropathy) | Removal of autoantibodies                                                | Albumin           | MG and rituximab             | 5–6 treatments over 10–14 days until improvement or stabilization of neurological response     | Clinical response; Nerve conduction studies; IgG and IgM titers                         | Frequency: 2–3/week until improvement, then tapered, e.g., weekly, or monthly            |
| Lambert–Eaton myasthenic syndrome                                      | Removal of autoantibodies                                                | Albumin           | Aminopyridines, possibly cholinesterase inhibitors; immunosuppression if symptomatic treatment is insufficient | 1–1.5 TPV daily or on alternate days until clinical response                               | Clinical response                                                                   |                                                                                        |
| Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT) or Hashimoto’s encephalopathy | Removal of autoantibodies                                                | Albumin           | Corticosteroids, MG, azathioprine, cyclophosphamide, potentially monoclonal antibody therapy | 1–1.5 TPV daily or on alternate days; 3–9 procedures until clinical response             | Clinical response                                                                   | Utilized in patients who have failed to respond to first-line therapy with corticosteroids |
| HIT with progressive thrombosis                                         | Removal of platelet-activating HIT antibodies                             | albumin, plasma   | Non-heparin anticoagulation   | 1–1.5 TPV daily or on alternate days until clinical response                                 | Clinical response; HIT antibody levels                                                |                                                                                        |
| Cryoglobulinemia vasculitis                                            | Removal of cryoglobulins                                                 | Albumin           | Corticosteroids, cyclophosphamide, rituximab | 1–1.5 TPV every 1–3 days; 3–8 sessions until disease control                               | Clinical response                                                                   |                                                                                        |
| Pancreatitis with severe hypertriglyceridemia                         | Decrease of triglyceride levels, removal of inflammatory cytokines, and potential replacement of deficient lipoprotein lipase | Albumin, plasma   | Dietary restriction, lipid-lowering drugs, insulin, heparin | TPV 1–1.5 daily for 1–3 days until clinical response and triglyceride levels               | Clinical response; triglyceride levels                                                |                                                                                        |
| Paraneoplastic neurological syndromes                                  | Removal of autoantibodies                                                | Albumin           | Antitumor therapy, immunosuppression (corticosteroids, IVG) | 1–1.5 TPV daily or on alternate days; 5–6 procedures up to 2 weeks until clinical response | Clinical response                                                                   |                                                                                        |
| Specific types of poisoning                                            | Removal of toxic substances with high protein-binding capacity and low distribution volume | Albumin, plasma   | Gastric lavage, activated charcoal (depending on toxic substance); multiorgan support          | 1–2 TPV daily until clinical response                                                   | Clinical response                                                                   |                                                                                        |
replacement should be, or be derived from, healthy donor plasma [1].

**Kinetic models**

Kinetic models for prediction of substance removal have been developed [10]. The half-life and volume of distribution of the substance to be removed must be considered when planning the intensity and frequency of TPE sessions. The plasma volume to be replaced is determined by calculating the total blood volume and the total plasma volume (TPV) of the patient [11]. For a substance that is neither rapidly synthesized nor redistributed and limited to the intravascular space, the first session of plasma exchange will remove 65–70% of the target substance. With additional plasma volumes exchanged, the absolute amount removed becomes progressively smaller due to the exponential nature of the removal (Fig. 2). The second session will remove an additional 23% and the third session only an additional 9% of the target substance. The net reduction will be affected by the redistribution from extravascular to intravascular compartments, production rate and by volumes of distribution. For example, one standard TPE session replacing 1.2 times the TPV will remove 10 g of IgG and 0.3 g of IgM due to the amount of IgG present in the intravascular space and its ability to redistribute from the extravascular compartment, which does not occur in an appreciable amount with IgM [12]. It also depends on the level of IgG at baseline (Fig. 2). In patients who are IgG depleted, TPE can replace the missing IgG [13].

The 2019 ASFA recommendations suggest exchanging 1.0–1.5 times the individually calculated TPV [2]. However, several clinical studies have shown a frequent failure to reach this TPE target [14]. A study in Germany reports exchanging only 0.4–1.0 times the estimated TPV.
Therapeutic goals of TPE
The therapeutic goals of TPE depend on the pathophysiology of the disease. For instance, in Waldenström macroglobulinemia, the goal is to decrease the IgM level to reduce plasma viscosity and eliminate symptoms of hypoperfusion. In TTP, the aim is to raise the platelet count above 150,000/µL and reversing hemolysis by removing anti-ADAMTS13 inhibitory antibodies, removing ultralarge von Willebrand factors multimers and replacing ADAMTS13 enzyme [19]. In myasthenia gravis, the aim is to achieve a rapid clinical stabilization by removing acetylcholine receptor antibodies, especially in case of myasthenic crisis. In GBS, the goal is to improve muscle strength and to reduce the need for mechanical ventilation and hasten recovery. Table 1 shows the main parameters to monitor and endpoints for the different TPE indications in the ICU (Table 1).

Diagnostic workup for TPE indications and monitoring
TPE is used in various medical conditions. The diagnostic work-up serves to identify the underlying disease and determine its characteristics (Table 2). During TPE, close monitoring is essential to prevent adverse events and to ensure efficacy and safety. The criteria for discontinuing TPE should be determined a priori. Many routine biomarkers (e.g., C-reactive protein (CRP), creatinine, bilirubin etc.) will be reduced after a TPE session, potentially for many hours, and therefore, must be interpreted with caution. Changes in the amount of a substance removed by TPE may not necessarily represent improvement in the disease process and additional evidence of clinical response such as symptom resolution should be sought (Table 1S). Similarly, a decrease in CRP level after TPE does not necessarily mean that inflammation and/or infection are under control.

Technical aspects
Machines and devices
During TPE, the plasma can be separated from the corpuscular components of the blood by centrifugation, membrane filtration, or both [20]. Centrifugation is based on the differences in density of the various blood components. Mature red blood cells (RBCs) have the greatest relative density, followed by young erythrocytes (neocytes), granulocytes, mononuclear cells, platelets and, finally, plasma. Filtration takes advantage of differences in particle size to separate plasma from cells.

Currently licensed TPE devices can operate with a continuous or an intermittent flow [21]. Both, centrifugal and membrane-based devices are available. In apheresis units based in transfusion medicine or hematology departments, TPE is usually performed with centrifugal systems (cTPE) that often use citrate for anticoagulation. In most nephrology departments and ICUs, the preferred devices are membrane-based (mTPE), including multifunctional renal replacement therapy (RRT) machines. In both cTPE and mTPE, the cell-rich blood that remains after plasma removal is mixed with the replacement fluid (e.g., albumin, plasma, or crystalloid) and returns to the patient to prevent hypovolemia. To reduce costs and donor exposures, up to 30% of the replacement fluid may be a suitable crystalloid. In low-resource healthcare systems, plasma, crystalloid, or non-plasma colloid beyond 30% of the replaced volume may be used for replacement due to the expense of albumin substrates, and availability and safety profile of plasma products.

Plasma removal efficiency (PRE) is the metric used to compare TPE devices. It describes the fraction (%) of plasma that passes through the device and is removed per procedure. PRE estimate may vary according to the...
| Disease                                                                 | Specific laboratory tests                                                                 | Diagnostic imaging | Special diagnostic tests                                                                 |
|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|--------------------|------------------------------------------------------------------------------------------|
| Acute inflammatory demyelinating polyradiculoneuropathy (Guillain–    | Serum IgG antibodies to GQ1b                                                              | Spinal MRI         | Lumbar puncture (elevated CSF protein) Electrodiagnostic studies (i.e., EMG and nerve conduction studies) |
| Barre syndrome)                                                        |                                                                                           |                    |                                                                                          |
| Anti-glomerular basement membrane disease (Goodpasture syndrome)       | Urine analysis (hematuria, proteinuria, cellular casts)                                    | Chest CT           | Kidney biopsy                                                                             |
|                                                                        | Renal function (creatinine)                                                                |                    |                                                                                          |
|                                                                        | Anti-GBM antibodies (serum, kidney)                                                        |                    |                                                                                          |
|                                                                        | ANCAps (MPO, PR3)                                                                          |                    |                                                                                          |
| Hyper-viscosity syndrome (in hyper-gammaglobulinemia, especially       | M component quantification                                                                 | Eye fundus         |                                                                                          |
| Waldenstrom macroglobulinemia)                                         | Viscosity measurement                                                                       | examination        |                                                                                          |
| Catastrophic antiphospholipid syndrome                                  | Lupus anticoagulant IgG and IgM anticoagulipin antibodies by ELISA                           | CT to rule out malignancy |                                                                                          |
|                                                                        | Anti-beta2-GP I antibodies; IgG and IgM by ELISA                                          |                    |                                                                                          |
|                                                                        | Testing for DIC, HIT II, TMA                                                                |                    |                                                                                          |
| Myasthenia gravis                                                      | Acetylcholine receptor antibodies                                                          | CT or MRI of the mediastinum | Repetitive nerve stimulation test                                                        |
|                                                                        | Receptor-associated protein, MuSK-Ab                                                      |                    |                                                                                          |
|                                                                        | Low-density LRP4 antibodies                                                                |                    |                                                                                          |
| N-methyl-D-aspartate receptor antibody encephalitis                    | Antibodies in serum and CSF (IgG antibodies to GluN1)                                      | MRI                | CSF, EEG, Rule out malignancy                                                            |
| Thrombotic thrombocytopenic purpura                                    | Blood smear                                                                                | CT and MRI         | ECG, Echocardiography                                                                    |
|                                                                        | ADAMTS13 activity and inhibitor                                                            |                    |                                                                                          |
|                                                                        | Hemolytic parameters                                                                       |                    |                                                                                          |
|                                                                        | Stool tests (cultures and Shiga toxin)                                                    |                    |                                                                                          |
|                                                                        | Troponins                                                                                  |                    |                                                                                          |
| Thyroid storm                                                          | TSH, T4, and T3 Thyrotop receptor antibodies                                              | Echocardiography   | ECG                                                                                      |
|                                                                        |                                                                                            | Thyroid ultrasound |                                                                                          |
| Acute liver failure                                                    | Liver enzymes                                                                              | Abdominal Doppler ultrasonography | Liver biopsy (e.g., malignancy) Echocardiography (hepato-pulmonary syndrome) |
|                                                                        | Coagulation profile (including prothrombin time, INR and fibrinogen and TEG or equivalent, consider ADAMTS13 if pregnancy related and concern re TTP/ATUS) | Alternative: abdominal CT |                                                                                          |
|                                                                        | Complete blood counts and renal biochemistry                                              |                    |                                                                                          |
|                                                                        | Urine toxicology screen and serum paracetamol level                                        |                    |                                                                                          |
|                                                                        | Viral hepatitis screen + viral PCR if clinically pertinent (CMV, HSV, EBV)                  |                    |                                                                                          |
|                                                                        | Pregnancy test                                                                             |                    |                                                                                          |
|                                                                        | Autoimmune markers                                                                         |                    |                                                                                          |
|                                                                        | Caeruloplasmin level                                                                        |                    |                                                                                          |
|                                                                        | Arterial ammonia                                                                           |                    |                                                                                          |
|                                                                        | Arterial blood gas and lactate                                                             |                    |                                                                                          |
|                                                                        | Ferritin, triglycerides if HLH considered as a cause of ALF                               |                    |                                                                                          |
| ANCA-associated vasculitis/anti-GBM disease                            | ANCAps (MPO, PR3)                                                                          | CT (head, orbits, mastoids, neck, thorax) | Biopsy of an affected organ                  |
|                                                                        | Anti-GBM antibodies                                                                         |                    |                                                                                          |
|                                                                        | Antinuclear Antibodies                                                                      |                    |                                                                                          |
|                                                                        | C3 and C4                                                                                  |                    |                                                                                          |
|                                                                        | Cryoglobulins                                                                              |                    |                                                                                          |
|                                                                        | Urinary sediment                                                                           |                    |                                                                                          |
|                                                                        | Tuberculosis screen                                                                        |                    |                                                                                          |

*MRI* magnetic resonance imaging, *CSF* cerebrospinal fluid, *EMG* electromyogram, *ANCA* antineutrophil cytoplasmic antibody, *MPO* myeloperoxidase, *GBM* glomerular basement membrane, *CT* computed tomography, *DIC* disseminated intravascular coagulation, *HIT* heparin-induced thrombocytopenia, *TMA* thrombotic microangiopathy, *ELISA* enzyme-linked immunosorbent assay, *MuSK-Ab* antibodies to muscle-specific kinase, *EEG* electroencephalogram, *TSH* thyroid-stimulating hormone, *T4* thyroxine, *T3* triiodothyronine, *ECG* electrocardiogram, *BAL* bronchoalveolar lavage, *INR* International Normalized Ratio, *PR3* proteinase 3, *ALF* acute liver failure, *HLH* hemophagocytic lymphohistiocytosis, *TTP* thrombotic thrombocytopenic purpura, *TEG* thromboelastography, *aHUS* atypical hemolytic uremic syndrome
mathematical formulas used [22–26]. With cTPE devices, PRE is faster and higher than with mTPE devices [12, 26]. Rates of removal are comparable with cTPE and mTPE for IgG but not for fibrinogen [12].

**Vascular access**

The choice of vascular access for TPE depends primarily on the method used: cTPE typically requires lower blood flow rates (Qb) (50–120 mL/min) than mTPE (150–200 mL/min) [27]. A lower Qb enables the use of narrower catheters such as peripheral devices (e.g., 18-Gauge needle) or standard triple-lumen central venous catheters (e.g., 7 Fr). With a peripheral vein, single-needle access is feasible when using cTPE [28] but might increase the treatment time. Peripherally inserted central catheters are not suitable because their narrow catheter gauge will collapse with the negative pressures exerted during TPE [29]. The mTPE devices often require higher Qb and, therefore, wider catheters such as temporary hemodialysis catheters or large-diameter dual-lumen catheters (e.g., 13.5 French) [30]. The optimum characteristics of a catheter for TPE include rigid walls, a large diameter, and a short length to reduce resistance and decrease instrument alarms. Machines used for cTPE can concentrate RBCs to a hematocrit of 80% or higher, which allows for more plasma per volume to be processed compared to mTPE devices [11]. A higher Qb is needed with mTPE devices as they usually extract only about 30–35% of processed plasma to prevent RBC damage from a high hematocrit. Thus, with mTPE devices three or four times more plasma volume must be processed to remove similar plasma volume as with cTPE devices.

**Anticoagulation**

Anticoagulation for TPE aims to achieve a delicate balance between preventing circuit failure with loss of expensive blood components and preventing bleeding. Systemic heparin and regional citrate are the most common anticoagulants, while epoprostenol can also be used, when citrate is unavailable, and heparin is contraindicated. In the past, citrate was generally used for cTPE and heparin for mTPE, but citrate is now also used for mTPE [12, 31, 32]. According to the World Apheresis Registry, in which two-thirds of apheresis procedures were therapeutic, 73% of procedures were provided with citrate anticoagulation [33].

Both heparin and citrate anticoagulation have advantages and drawbacks (Table 2S). The risk of bleeding during TPE is lower with citrate than with heparin. However, when citrate is used with a mTPE device, side effects are more frequent, mainly because more citrate is required as a result of a higher Qb, plus, removal of less plasma leads to more citrate entering the patient’s systemic circulation [11]. Symptomatic hypocalcemia is also more common with citrate and can be prevented by prophylactic calcium administration [34]. Commercially available mTPE devices with integrated citrate administration adjusted for Qb and calcium supplementation according to effluent rate reduce the risk. When using heparin for anticoagulation, estimation of the required dosage should factor in extracorporeal losses of the drug and its cofactor antithrombin [35]. Moreover, antithrombin loss may hamper anticoagulation with heparin as well as the interpretation of chromogenic anti-Xa assays that add exogenous antithrombin.

**Fluid replacement**

Albumin or plasma can be used as replacement fluid, alone or in combination, and with or without the addition of a crystalloid such as saline. Albumin is used most often, as it is associated with a lower frequency of allergic or immune reactions (e.g., transfusion-related acute lung injury) compared to plasma and not associated with a risk of transfusion transmitted disease [12, 36, 37]. Table 3S summarizes pros and cons of each alternative (Table 3S). When albumin is used as replacement solution, metabolic acidosis may be seen after the TPE session because albumin has an acidic profile [38]. Albumin substitution may also affect the concentrations of fibrinogen and other coagulant factors resulting in profound derangement of thromboelastography parameters [39].

Plasma is indicated when aiming to replace plasma components (e.g., ADAMTS13 in TTP). Despite the absence of hard evidence, many centers also use plasma to prevent depletion of coagulation factors (e.g., if a bleeding diathesis is present or an invasive procedure is planned). Established guidelines for hemostasis monitoring/management during TPE are lacking but the extracorporeal losses of both pro- and anticoagulant factors need to be considered [40].

A recent survey by an ASFA subcommittee found wide practice variation in the type of replacement fluid but the potential bleeding risk most often determines the choice [41]. Because of the large volume, the number of donor exposures, and often prolonged duration of therapy, the risk of allergic reactions is higher with plasma than with albumin, and some centers administer antihistamines and/or glucocorticoids when using plasma [42]. When plasma is used as replacement solution, metabolic acidosis may occur because of metabolism of citrate used as anticoagulant and citrate present in stored plasma. For every citrate molecule metabolized, there is a consumption of hydrogen ions and production of three sodium bicarbonate molecules, thus increasing serum pH levels [43].
Crystalloid can be added for cost-containment and in patients with hyperviscosity syndrome. However, replacing plasma with crystalloid carries a risk of hypotension if the proportion of replacement with crystalloid exceeds 30% [44]. In this setting, significant fluid shifts can occur as water follows its concentration gradient from the intravascular space into the extravascular space. When crystalloid is used as a portion of the replacement, it should be administered at the beginning of the exchange and not at the end to avoid significant fluid shifts and hypotension. Hydroxyethyl starch (HES) is no longer recommended in critically ill patients due to its harmful effects on both renal function and coagulation. However, it is still occasionally used as a replacement fluid (e.g., 3% HES with 5% human albumin), especially in low-resource healthcare systems [45, 46]. It may also be used in patients who refuse blood products.

**Clinical response**
The expected benefits and potentially deleterious effects of TPE are dependent on the timing of the procedure with respect to the onset of the illness, the volume of fluid exchanged, the type of replacement solution, and the frequency and intervals of plasma removal. The individual criteria for “clinical response” are highly disease specific, ranging from changes in individual or multiple hematological parameters, antibody concentrations or biochemistry to improvement of clinical signs and symptoms. The impact of TPE can be rapid or slow and may last for weeks to months, depending on the underlying disease. However, long-term effects, including psychological well-being and the risk of chronic organ dysfunction beyond the acute illness are rarely reported.

**Complications**
TPE is a relatively safe procedure and usually well tolerated. Complications include catheter-related and procedure-related events. The incidence of adverse events has declined over time [47, 48] and now ranges from 5 to 36% depending on vascular access used, type of replacement fluid, and anticoagulation (Table 4S). Catheter-related infections, pneumothorax, and local bleeding have been reported in 0.4–1.6% of patients [49, 50]. In critically ill patients, bleeding disorders were rare (<10%) but catheter dysfunction was the most common complication (32%) [30]. Complication rates were similar with mTPE and cTPE [30]. Potentially life-threatening complications, dominated by anaphylactoid reactions and severe hypotension, have been reported in 1–2% of TPE sessions in critically ill patients [30, 51]. They should be minimized by the judicious choice of a vascular access in close collaboration with the apheresis specialist.

Citrate anticoagulation and plasma replacement are risk factors for hypocalcemia and paresthesia [52]. Plasma replacement is associated with a higher risk of anaphylactoid reactions. On the other hand, replacement with albumin does not correct the depletion and balancing of coagulation factors and immunoglobulins, resulting in a potential risk of bleeding and infection, respectively.

**Drug removal by TPE**
Data on drug removal by TPE are scarce and based on case reports or case series only [53, 54]. For most drugs, either no information is available, or it is not important. For highly protein-bound drugs with a low volume of distribution, and for chimeric antibodies, there is very effective removal. Factors associated with clinically meaningful drug removal include drug characteristics (volume of distribution, protein-binding affinity, rate of endogenous clearance, distribution half-life, dose-related pharmacodynamics), TPE characteristics (volume of plasma removed, interval between sessions, time between first and last session) and timing of drug administration [54–57]. Important inter- and intra-individual differences in pharmacokinetics and the multi-compartmental kinetic patterns seen during TPE can make predictions very difficult.

Antibiotic removal during TPE was reviewed recently [53, 56]. Whether an antibiotic should be administered before or after TPE depends also on its pharmacodynamic characteristics. Aminoglycosides can be best administered before the procedure to benefit from both a high peak with bactericidal effect and reduced toxicity related to a low trough level through extracorporeal removal. Beta-lactam plasma levels, on the other hand, should be maintained above the minimum inhibitory concentration which often requires a supplementary dose post-procedure. Monoclonal antibodies such as rituximab have a small volume of distribution and a long distribution half-life and therefore are significantly removed by TPE [58]. During TPE, total clearance of the drug decreases over time as the plasma levels decrease [59]. Although levels of monoclonal antibodies correlate with clinical effects, they may not correlate with pharmacodynamic markers (i.e., the CD20+ B-cell count for rituximab) [54]. Significant removal of enoxaparin, tacrolimus, and mycophenolic acid during TPE has been reported [60, 61]. Most studies involved administering medications after TPE and scheduling the next TPE session 24–36 h later. In general, therapeutic drug monitoring should be applied whenever possible in critically ill patients undergoing serial TPE sessions, especially if the drug has a narrow therapeutic index. Timing of sampling
should account for post-procedure redistribution with rebound of plasma concentration.

**Unanswered questions and research agenda**

**Potential novel mechanisms and emerging ICU indications for TPE**

For the most urgent TPE indications in critical care listed in Table 1, the efficacy of TPE is thought to stem from the removal of pathogenic substances and/or provision of deficient protective molecules. This classical blood purification concept may apply to systemic inflammatory syndromes encountered in a wide variety of critical conditions, but timing and anti-/pro-inflammatory balance may be pivotal in determining benefit versus potential detriment. Thus, inflammatory processes with consumptive coagulopathy ranging from thrombocytopenia to disseminated intravascular coagulation might respond to TPE. Furthermore, TPE removes damage-associated molecular patterns (DAMPs) that are released by injured cells and may trigger and perpetuate multiorgan dysfunction. In patients with sepsis and multiorgan dysfunction, TPE can lead to shock reversal and improve vascular permeability and coagulation abnormalities, while also producing a trend toward improved survival [62–64].

Given the ability of TPE to modulate systemic inflammation and coagulopathy, potential benefits in patients with severe COVID-19 have generated interest [65, 66]. Moreover, TPE can correct the increased von Willebrand factor multimer and the decreased ADAMTS13 activity in COVID-19 patients [67]. Faster recovery but no effect on mortality was shown in one small randomized controlled trial [68]. Many studies, including randomized controlled trials, are ongoing to test various hypotheses using slightly different protocols. Apart from sepsis, clinical scenarios characterized by a systemic inflammatory response that may improve with TPE include hemophagocytic lymphohistiocytosis, macrophage activation syndrome, chimeric antigen receptor T-cell-associated cytokine release syndrome, severe pancreatitis, and severe burns. So far, the current evidence remains limited to case series and uncontrolled observational studies. Finally, TPE has been used recently in refractory cases of vaccine-induced thrombosis and thrombocytopenia which could be added to the list of rescue therapy although evidence is still limited [69].

**Initiation of TPE**

The appropriate timing of TPE initiation needs to be determined. Biomarker levels, antibody titers, or clinical symptoms that support TPE initiation vary across indications. Specific cut-offs associated with poor outcomes need to be identified. Of note, the inflammatory syndromes encountered in the ICU may also serve as markers for monitoring of the effectiveness of TPE, such as markers of endothelial activation and primary hemostasis. Although trauma and sepsis are different entities, in both, elevations of glycocalyx-shedding biomarkers such as syndecan-1 and heparan sulfate are associated with poor outcomes [70] and their levels can be reduced with TPE [71]. Also, an imbalance between ADAMTS13 and von Willebrand factor is found in both sepsis and trauma. Specific cut-offs have been suggested, but whether these are useful to guide TPE remains unknown.

**Comparison of TPE to other interventions**

For most conditions, the efficacy of TPE compared to other techniques is not known. In GBS and myasthenia gravis, the effectiveness of TPE was compared to that of IVIG or a combination of both [72]. For conditions related to a pathogenic antibody, limited-level evidence suggests that TPE and more selective immunoadsorption techniques might have similar efficacy, but more studies are needed. Also, new data may challenge the benefit of TPE in some instances. Trials such as the PEXIVAS study led the AFSA to change severe ANCA-associated vasculitis from a category I to category II indication for TPE [73, 74].

**Technical aspects of TPE**

Little evidence supports the standard TPE regimens in ICU patients. More specifically, all current regimens were developed based on long-term experience with ward patients or outpatients. ICU patients likely have altered volumes of distribution due to organ failures, capillary leakage, and/or hypoalbuminemia. Ideally, TPE regimens should be tailored to the needs of the individual patient. More information about the optimal TPE intervals and volumes for critically ill patients is needed, as well as the optimal replacement solutions and the stopping cut-offs associated with a low risk of rebound.

**Conclusions**

TPE is an established therapy in modern critical care. It includes centrifugal and membrane-based techniques and requires fluid replacement with plasma or albumin solution. We have summarized the key points for the non-TPE specialists (Table 3). Although TPE is considered as first- or second-line therapy in many disorders, significant knowledge gaps remain, especially with regard to the exact triggers and cut-offs for initiation, optimal markers for monitoring and triggers for discontinuation. Furthermore, the interpretation of routine laboratory blood tests and drug dosing are challenging during TPE. More observational and interventional studies are needed to fill the existing knowledge gaps, to identify patients who are likely
### Table 3 Key points for the non-TPE specialists

The organization of the TPE service differs between institutions. In many hospitals, specialist apheresis physicians and nurses provide TPE for ICU patients in close collaboration with intensivists. Since critically ill patients are highly vulnerable and at risk of hemodynamic instability, electrolyte disturbances, and coagulation disorders, close monitoring is needed during TPE. The choice of intravenous access (peripheral or central) should be carefully reviewed. TPE can be performed in the outpatient and inpatient setting. The decision regarding ICU admission tests on the clinical status and not on the need for TPE.

The decision to initiate TPE should be based on the rationale that there is a presence of a substance causing a potentially life-threatening disruption that can be removed by TPE or the need for replacing a deficient substance to improve clinical outcomes. It should be evidence-based whenever possible although appropriate trials are lacking in most settings.

The following tests must be performed before TPE. ABO Rh blood group and, if appropriate, an RBC antibody screen (in case plasma or RBC priming is needed); ionized calcium, magnesium, and potassium (which may be affected by citrate anticoagulation); complete blood cell count (to determine device settings and to exclude significant cytopenia that may require correction); and coagulation tests (activated partial thromboplastin time, partial thromboplastin time, prothrombin time, and fibrinogen).

The changes in hemostasis and coagulation tests induced by TPE must be considered when interpreting test results and making clinical decisions. For example, instituting oral anticoagulation regimens should be avoided during a string of TPE sessions, since dosing can be challenging given the removal of coagulation factors, combined with the potential addition of coagulation factors (in case of replacement with plasma)

Aside coagulation tests, TPE alters most laboratory variables, including serological tests, and inflammatory markers. Therefore, sample collection must be timed accordingly. Furthermore, circulating biomarkers such as troponin, brain natriuretic peptide, CRP, and LDH are no longer reliable for assessing the disease course.

Ideally, repeated TPE requires therapeutic drug monitoring for antibiotics, anticoagulants, and several medications.

More is not necessarily better. Standard TPE replaces 1.0 to 1.5 times the TPV. Given removal kinetics, replacing two or three times more does not result in a two- or threefold increase in efficacy.

In patients who also require renal replacement therapy (RRT), TPE should be performed first unless there are potentially life-threatening electrolyte disturbances mandating urgent RRT. The volume of replacement fluid given during TPE can be removed during RRT. In addition, fluid shifts that occur following RRT may result in hypotension when blood enters the extracorporeal circuit of the apheresis device during the TPE requiring fluid resuscitation which negates the benefit of volume removal during RRT. Tandem procedures combining TPE and RRT can also be performed in experienced centers.

TPE involves replacement with colloids whose oncotic pressure is like the removed plasma. Therefore, in patients with volume overload before TPE, any decrease in the replacement fluid volume will decrease the intravascular volume and potentially cause hypotension. In contrast to dialysis, TPE cannot remove free water, which would lead to hemococoncentration and fluid shifts from the extravascular to the intravascular compartment.

TPE has the potential to remove medications and there is limited pharmacokinetic data available. Practical recommendations to address this potential adverse effect include: once daily medications should be administered after TPE, not before; administration of IV medications should be avoided immediately prior to and during TPE; oral medications should be avoided within four hours prior to TPE to allow for adsorption and redistribution prior to the start of the TPE; chimeric antibodies, monoclonal antibodies, and IVIG are effectively removed and timing of administration of these agents and TPE must be coordinated to allow for maximum medication dwell time.

In some clinical situations (e.g., Guillain–Barré syndrome), TPE and intravenous immunoglobulins (IVIG) have equivalent efficacy. Combining the two in these scenarios is not recommended and TPE may be reserved in case of failure to IVIG.

---

**To benefit from TPE and to avoid TPE in those who will not benefit or may come to harm.**

**Supplementary Information**

The online version contains supplementary material available at [https://doi.org/10.1007/s00134-022-06793-z](https://doi.org/10.1007/s00134-022-06793-z).

**Author details**

1 Médicine Intensive et Réanimation, Hôpital Saint-Louis, APHP, Paris, France.
2 Division of Pulmonary and Critical Care, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 3 Apheresis Unit, Immunohematology, Hôpital Saint-Louis, APHP, Paris, France. 4 Medical Intensive Care Unit, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. 5 Unità Alergosi e Terapie Cellule, Banc de Progenitors Hematopoietici, Servei d’Hemoteràpia i Hemostàsia, IMH, Hospital Clinic, IDIBAPS, Barcelona, Spain. 6 Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland. 7 Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada. 8 Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands. 9 Nephrology | Rheumatology | Blood Purification, Academic Teaching Hospital Braunschweig, Brunswick, Germany. 10 Department of Intensive Care Medicine and Anesthesiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy. 11 Division of Pulmonary, Critical Care and Sleep Medicine, University of New Mexico School of Medicine, New Mexico, USA. 12 Department of Critical Care, King’s College London, Guy’s & St Thomas’ Hospital, London, UK. 13 Critical Care Unit, King’s College Hospital NHS Foundation Trust, London, UK. 14 Anesthesia and Intensive Care, Policlinico San Martino, Genoa, Italy. 15 Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 16 Division of Cellular and Molecular Medicine, Clinical Department and Laboratory of Intensive Care Medicine, KU Leuven University, Leuven, Belgium. 17 Penn State Health, Hershey, USA. 18 Institute of Liver Studies, King’s College Hospital NHS Foundation Trust, London, UK. 19 Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA.

**Acknowledgements**

The Nine-I Investigators: Austria: Nina Buchtele, Department of Medicine I, Vienna; Thomas Staudinger, Department of Medicine I, Vienna; Gottfried Heinz, Department of Medicine II, Vienna; Günther Sengelke, Department of Medicine III, Vienna; Christian Zauner, Department of Medicine III, Vienna; Peter Jaksch, Department of Thoracic Surgery, Vienna; Karin Amrein, Department of Internal Medicine, Graz; Peter Schellongowski, Department of Medicine I, Medical University of Vienna, Vienna, Austria; Thomas Staudinger, Department of Medicine I, Medical University of Vienna, Vienna, Belgium: Anne-Pascale Meert, Institut Jules Bordet, Brussels; Dominique Benoît, Ghent University Hospital, Ghent; Fabio Silvio Taccone, Department of Intensive Care, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels. Brazil: Ana Paula Pierre de Moraes,
Hospital de Câncer do Maranhão; William Viana; Hospital Copa d’Or; Guilliana Moralez, Hospital GetulioVargas, Rio de Janeiro; Thiago Lishoa; Hospital Santa Rita, Santa Casa de Misericórdia, Porto Alegre; Marco Soares, Department of Critical Care and Graduate Program in Translational Medicine, D’Or Institute for Research and Education, Programa de Pós-Graduação em Clínica Médica, Rio de Janeiro, Jorge Salluh; Department of Critical Care and Graduate Program in Translational Medicine, D’Or Institute for Research and Education, Programa de Pós-Graduação em Clínica Médica, Rio de Janeiro; U. V. Silva, ICU, Fundação Pio XII—Hospital de Câncer de Barretos, Barretos. Canada: Sumech Shah, Mount Sinai Hospital, Toronto; Sangeeta Mehta, Department of Medicine and Interdepartmental Division of Critical Care Medicine, Sinai Health System, University of Toronto, Toronto, Ontario; Laveena Munshi, Department of Medicine and Interdepartmental Division of Critical Care Medicine, Sinai Health System, University of Toronto, Toronto, Ontario. Czech republic: Balik Martin, Department of Critical Care, Prague; Karvunidis Thomas, Department of Critical Care, Pilsen; Katerina Rusinova, Department of Anesthesiology and Intensive Care Medicine and Institute for Medical Humanities, 1st Faculty of Medicine, Charles University in Prague and General University Hospital Prague, Prague. Denmark: Jonas Nelsen, Rigshospitalet, Copenhagen; Ann M. Moeller, Herlev university hospital, UCPH, Herlev; Anders Perner, Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen; Ramin Brandt Bukan, Herlev university hospital, Department of Anesthesiology; L. Herlev; Lene Nielson, Intensive Care Department, University of Southern Denmark, Department of Anaesthesia and Intensive care, Odense University Hospital. Finland: Docent Anne Kuitunen, Department of Critical Care, Tempere; Mia Valkonen, Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital. France: Antoine Rabbat, Hôpital Cochin, Paris; Isabelle Vinatier, CHD de Vendée, La Roche Sur Yon; Kadia Klouche, Laura Platon, CHU, Montpellier; Martine Nuyinga, CHG Victor Provo, Roubaix; Alexandre Demoule, Julien Mayaux, CHU Pitié-Salpêtrière, Paris; Florent Wattel, CHU, Lyon Sud; Akira Cherkam, CH Sud Essonne, Etampes; Caroline Lemaître, Elise Artaud-Macari, University Hospital, Medical Intensive Care, Rouen; Elie Azoayay, Department of Critical Care, Saint-Louis Paris; Virginie Lemalle, Department of Critical Care, Saint-Louis Paris; Virginie Soupott, Department of Critical Care, Saint-Louis Paris; Michael Darmon, Department of Critical Care, Saint-Louis Paris, Paris; Lara Zafra, Department of Critical Care, Saint-Louis Paris; Sandrine Valade, Department of Critical Care, Saint-Louis Paris; Djamel Mokart, IPCC Marseille, Department of Critical Care; Benjamin Gaborit, CHU Nantes, Department of Critical Care; Emmanuel Canet, CHU Nantes, Department of Critical Care, Amelie Seguin, CHU Nantes, Department of Critical Care, Sylvie Chevret, ECSTRA Team, Biostatistics and Clinical Epidemiology, ULM 1153, INSERM, Paris Cité University; Nicolas Terz, CHU Grenoble Alpes, Service de réanimation médicale, Faculté de Médecine de Grenoble, INSERM, U1042, Université Grenoble-Alpes; Grenoble; Carole Schwebel; CHU Grenoble Alpes, Service de réanimation médicale, Faculté de Médecine de Grenoble, INSERM, U1042, Université Grenoble-Alpes, Grenoble; Aichl Koschütz, Department of Medical Intensive Care Medicine, University Hospital of Angers, Angers; Fabrice Brunet, Centre Hospitalier de Versailles, Medical-Surgical Intensive Care Unit, Le Chesnay, France; Frédéric Péne, Medical ICU, Cochin Hospital, Paris; Anne Sophie Moreau, Critical Care Center, CHU Lille, School of Medicine, University of Lille; Christophe Girault, Normandie Univ, UNIROUEN, EA-3830, Rouen University Hospital, Department of Medical Intensive Care, F-76000, Rouen, France; Barrie, Medical Intensive Care Unit, La Source Hospital—CHR Orléans—Ile de France; Aisling Mc Mahon, Department of Critical Care, St James, Dublin; Brian Marsh, Department of Critical Care, Mater misericordia, Dublin; Ignacio Martin Loeches, Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James’s Hospital, and department of Clinical Medicine, Trinity College, Wellcome Trust-HRB Clinical Research Facility, St James’s Hospital, Dublin. Italy: Gilda Cinnella, Antonella Cotoia, Ospedali Riuniti, Department of Critical Care, Foggia; Massimo Antonelli, Agostino Gemelli University Hospital, Università Cattolica del Sacro Cuore, Rome; Luca Montini; Agostino Gemelli University Hospital, Università Cattolica del Sacro Cuore, Rome. Netherlands: Thomas Kaufmann, Department of Critical Care, Groningen, Dennis Bergmans, Department of Critical Care, Maastricht; Angelique Spoelstra-de Man, Department of Critical Care, Amsterdam; Peter Pickkers, Department of Critical Care, Amsterdam; Pleun Hemelraad, Department of Critical Care, Amsterdam; Precious Pearl Hague, Department of Critical Care, University Medical Center Groningen. Norway: Pål Klepstad, St. Olavs Hospital, Trondheim; Andreas Barratt-Due, Department of Emergencies and Critical Care, Oslo University Hospital, Oslo. Spain: Belen Encina, Val Hebron, Barcelona; Gabriel Moreno, Department of Critical Care, Bellvitge; Emilio Rodriguez Luis, Department of Critical Care, Santiago de Compostella, Llorenç Socías Crespi, Department of Critical Care, Palma; Jordi Rello, CIBERES, Universitat Autonoma de Barcelona, European Study Group of Infections in Critically Ill Patients (ESCCIP), Barcelona. United Kingdom: Victoria Metaux, King’s College Hospital, London. United States of America: Yadav Hemang, Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN; Philippe R. Bauer, Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN; Andy van de Louw, Penn State University College of Medicine, Division of Pulmonary and Critical Care Medicine, Hershey, Pennsylvania. Uruguay: Gaston Burghi, Terapia Intensiva, Hospital Maciel—Montevideo.

Declarations

Conflicts of interest
JC received speaker fees from Fresenius Kabi and Terumo Blood and Cell Technologies. IJX received speaker fees from Fresenius Medical Care and ExThera Medical.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 8 April 2022 Accepted: 20 June 2022 Published: 12 August 2022

References

1. Reeves HM, Winters JL (2014) The mechanisms of action of plasma exchange. Br J Haematol 164:342–351. https://doi.org/10.1111/bjh.12629
2. Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingen R, Meyer E, Pham HP, Schneideman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ (2019) Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher 34:171–354. https://doi.org/10.1002/jca.21705
3. Abe T, Matsu H, Abe R, Abe S, Asada H, Ashida A, Baba A, Eguchi K, Eguchi Y, Endo Y, Fujimon Y, Furuchi K, Furukawa Y, Furuya M, Futuya T, Hanafusa H, Hara W, Harada-Shiba M, Hasegawa M, Hattori N, Hattori M, Hidaka S, Hidaka T, Hirayama C, Ikeda S, Iamamura H, Inoue K, Ishizuka K, Ishizuka H, Ito I, Iwamoto H, Iwaki S, Kaigami M, Kaneko S, Kaneko N, Kanikura T, Kitagawa K, Kusao M, Lin Y, Maeda T, Makino K, Makino S, Matsuoka K, Matsugane T, Minematsu Y, Mineshima M, Miura K, Miyamoto K, Moriguchi T, Murata M, Manganuma M, Nakae H, Nanakawa S, Nohara A, Nomura K, Ochi H, Ohkubo A, Ohtake T, Okada K, Okado T, Okuyama A, Omokawa S, Oji S, Sakai N, Sakamoto Y, Sasaki S, Sato M, Seishima M, Shiga H, Shimohata H, Sugawara N, Sugimoto K, Suzuki Y, Suzukı M, Tajima T, Takikawa Y, Tanaka S, Taniguchi K, Tsichuda S, Tsikamotos T, Tsukamoto T, Tsukahara K, Ueda Y, Wada T, Yamada H, Yamada H, Yamaga T, Yamamoto K, Yokoyama Y, Yoshida N, Yoshitaka T, Yamaki K (2021) The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis. Ther Apher Dial 25:728–876. https://doi.org/10.1111/1744-9987.13749
4. Pham HP, Schwartz J (2019) Therapeutic plasma exchange in Guillain- Barre Syndrome and chronic inflammatory demyelinating polyradiculo-neuropathy. Pesse Med 48:338–346. https://doi.org/10.1016/j.pm.2019.03.016
5. Chevret S, Hughes RA, Arnaud D (2017) Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2.CD001798. https://doi.org/10.1002/14651858.CD001798.pub3
6. Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570–2581. https://doi.org/10.1056/NEJMc1602678
7. Barth D, Nabavi Moun R, Ng E, Nwe P, Bell V (2011) Comparison of Mx and PLEX in patients with myasthenia gravis. Neurology 76:2017–2023. https://doi.org/10.1212/WNL.0b013e31821e5505
8. Naciri Bennani H, Nobile J, Chevallier E, Terre F, Motte L, Giroux-Lathuile C, Bugnazer M, Imerouzouene F, Janbon B, Malvezzi P, Rostaing L, Jouve T (2021) Isoagglutinin removal by plasma centrifugation or filtration
